The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 11, 2008

Filed:

Aug. 09, 2001
Applicants:

Gil Tenne, Shoham, IL;

Mark L. Levitt, Hashmonaim, IL;

Anahit Karapetian, Tel Aviv, IL;

Inventors:

Gil Tenne, Shoham, IL;

Mark L. Levitt, Hashmonaim, IL;

Anahit Karapetian, Tel Aviv, IL;

Assignee:

Era-Massis, Inc., Wilmington, DE (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 1/00 (2006.01); G01N 1/18 (2006.01); G01N 33/554 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to a method for the early diagnosis of cancer in a subject, which is based on determination of the relative fraction of microorganisms derived from the feces of the subject, as compared to the total count of microorganisms in the same of corresponding sample. This relation has been found to be indicative of the presence or absence of cancer in said subject. After isolating at least one of the microorganisms from the fecal sample to form a so-called diagnostic sample, and incubating, for a sufficient time, the diagnostic sample with cancer cells. The microorganism being in an amount corresponding to its relative fraction in the original fecal sample, the cancerolytic activity of the microorganism/s is indicative to the presence or absence of cancer cells in the subject. The cancerolytic activity is expressed by terms of a tumor cell necrosis index (TCNI). Further, the method of the invention is based on determining level of expression or level of activity of L-PAR II in a fecal-derived microorganism/s sample, the level determined being also indicative of the presence or absence of cancer cells in the subject from which the fecal sample was derived.


Find Patent Forward Citations

Loading…